Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients With Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial
Ifinatamab Deruxtecan在Ideate-Lung01第2期試驗中繼續展示出對廣泛期小細胞肺癌患者良好的客觀緩解率
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients With Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial
Ifinatamab Deruxtecan在Ideate-Lung01第2期試驗中繼續展示出對廣泛期小細胞肺癌患者良好的客觀緩解率
譯文內容由第三人軟體翻譯。